Skip to main content

Decalcification of Breast Cancer Bone Metastases With EDTA Does Not Affect ER, PR, and HER2 Results.

van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, Menke-van der Houven van Oordt CW, Verheul HM, van Herpen CML, Jager A, Oosting SF, de Vries EGE, Schröder CP

Publication: Am J Surg Pathol (2019) • Vol 43 • Page 1355-1360PMID: 31283631View on PubMed

Purpose

This paper evaluated the potential effects introduced by different decalcification methods on immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR), and HER2 and determination of HER2 status by fluorescent in situ hybridization (FISH) and silver in situ hybridization (SISH).  Decalcification was simulated in formalin-fixed, paraffin-embedded (FFPE) breast tumor tissue by incubation in acetic acid, hydrochloric/formic acid, or EDTA for 24-48 h. Concordance between ER, PR, and HER2 status of the primary tumor and case-matched metastatic bone biopsies that were decalcified with EDTA (the optimal method of those evaluated)  was investigated.

Conclusion

Simulated decalcification of breast tumors with acetic acid or ETDA did not affect immunohistochemistry (IHC) staining, but hydrochloric/formic acid resulted in a decline in the percentage of ER, PR, and HER2 positive cases. While decalcification with  either acetic acid or hydrochloric/formic acid resulted in complete failure of FISH and SISH staining in all cases, decalcification with EDTA did not affect ISH results and thus was considered the optimal decalcification method. ER and PR IHC scores were discordant between the primary breast tumor and the case-matched EDTA-decalcified bone metastasis in 7.8% and 20.8% of cases, respectively; mean ER and PR expression were discordant in 40.3% and 66% of cases, respectively. While IHC HER2 scores were discordant between paired primary breast tumors and EDTA-decalcified bone metastases in 33/77 cases, overall HER2 status (both IHC and ISH results were considered) was concordant between paired primary breast tumors and the decalcified bone metastasis in all but one case. Clinically relevant discordance of hormone receptor status between primary and metastasized decalcified bone tumors was not correlated with disease-free survival (time between the primary tumor and the metastasis).

Studies (1)

Purpose

This study evaluated the potential effects introduced by different decalcification methods on immunohistochemical staining of estrogen receptor (ER), progesterone receptor (PR), and HER2 and determination of HER2 status by fluorescent in situ hybridization (FISH) and silver in situ hybridization (SISH).  Decalcification was simulated in formalin-fixed, paraffin-embedded (FFPE) breast tumor by incubation in acetic acid, hydrochloric/formic acid, or EDTA for 24-48 h. Tumors from 16 breast cancer patients were fixed in buffered formalin for 24-48 h, divided into seven blocks, and left untreated (control) or subjected to decalcification with EDTA (20% Titriplex III, 4% phosphate-buffered formalin, and 2% sodium hydroxide in distilled water), hydrochloric/formic acid (0.8% sodium citrate, 2% formic acid, and 1.5% hydrochloric acid in distilled water), or acetic acid (3.5-4% formaldehyde and 10% acetic acid in distilled water) for 24 or 48 h before paraffin embedding. Three cores were selected from each block incorporated in a tissue microarray and 3 µm-thick sections were stained for ER, PR, and HER2 with an autostainer. FISH and SISH were performed following the manufacturer’s recommendations and specimens were scored according to ASCO/CAP guidelines (ER and PR positive= 1-100% tumor cells stained; HER2 IHC positive= >10% tumor cells have complete membrane staining; HER2 ISH positive= dual ISH probe ratio ≥2.0) by a pathologist blinded to the decalcification method and time. Concordance between the primary tumor and a case-matched metastatic bone biopsy decalcified using the optimized decalcification method was also investigated for ER, PR, and HER2 status. Using the optimized decalcification method of 24-48 h incubation in EDTA, 77 paired breast tumor tissue and bone metastasis biopsy specimens (median tumor relapse time of 75.8 months, range of 0.6 to 293.5 months) were processed and analyzed as described above.

Summary of Findings

Simulated decalcification of breast tumor specimens with acetic acid did not affect ER, PR, or HER2 status determined by IHC compared to the untreated control tissue but resulted in failed SISH and FISH in 94% and 100% of cases, respectively. The use of hydrochloric/formic acid resulted in false-negative ER staining in 30% of cases, false-negative PR staining in 20% of cases, decreased HER2 IHC score from 3+ into 2+ in one case, and complete failure of FISH and SISH staining in all cases. Decalcification with EDTA did not affect the IHC status of any of the cases, resulted in SISH failure in one case, and perfect FISH concordance (100%) with the control specimen; thus, EDTA was considered the optimal decalcification method and was applied to bone specimens in all subsequent analyses. ER IHC scores were discordant between primary breast tumor and EDTA-decalcified bone metastasis in 7.8% of cases (P=0.219). Of the six discordant cases, five patients had an ER-positive primary tumor and an ER-negative decalcified bone metastasis, and one patient had an ER-negative primary tumor and an ER-positive decalcified bone metastasis. Mean ER expression was discordant (a median change in IHC expression of ≥20%) in 40.3% of cases (P=0.044), with an increase in ER expression observed in 17% of cases and a decrease in 24% of cases. PR IHC scores were discordant between the primary breast tumor and the EDTA-decalcified bone metastasis in 20.8% of cases (P=0.077), with a PR-positive primary tumor and negative decalcified bone metastasis biopsy for 15.6% of cases and a PR-negative primary tumor with a PR-positive decalcified bone metastasis biopsy in 5.2% of cases. Mean PR expression was discordant (a median change in IHC expression of ≥20%) in 66% of cases (P=0.009) with an increase in PR expression observed in 22% of cases and a decrease in 43% of cases. IHC HER2 scores were discordant between paired primary breast tumors and the EDTA-decalcified bone metastases in 33/77 cases, with a higher IHC HER2 score observed in the bone metastasis than the primary tumor in 25% (19/77) of cases and a lower score in 18% (14/77) of cases. HER2-negative status was 100% concordant between paired primary breast tumors and EDTA-decalcified bone metastases (n=66); conversely,  one case that was HER2-positive in the primary tumor (n=11) was HER2-negative in the bone metastasis. Clinically relevant discordance of both ER and PR status was observed in 6/77 cases (7.9%) and in HER2 status in 1/77 cases (1.3%); however, this was not correlated with disease-free survival (time between the primary tumor and the metastasis).

  • Biospecimens

    TissueBreast
    TissueBone
  • Preservation Types

    Formalin
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinTissue microarray
    DNATissue microarray
    DNAFISH
    DNAIn situ hybridization
    ProteinImmunohistochemistry
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    PreaquisitionDiagnosis/ patient condition
    Median tumor relapse time of 75.8 months (range of 0.6 to 293.5 months)
    Biospecimen AcquisitionBiospecimen location
    Breast cancer metastases to bone
    Primary breast tumor
    Analyte Extraction and PurificationDecalcification solution/ duration
    EDTA
    acetic acid
    hydrochloric/formic acid
    In situ hybridization SpecificTargeted nucleic acid
    HER2
    Immunohistochemistry SpecificTargeted peptide/protein
    ER
    HER2
    PR